Related Experiment Video
Updated: Nov 15, 2025

Author Spotlight: Illuminating New Avenues for Adipose Tissue Metabolism and Disease Prevention
Published on: October 6, 2023
Asprosin, a novel glucogenic adipokine: a potential therapeutic implication in diabetes mellitus
Munevver Gizem Hekim1, Muhammed Mirac Kelestemur2, Funda Gulcu Bulmus3
1Department of Physiology, Faculty of Medicine, Firat University, Elazig, Turkey.
Objectives:
We aimed to investigate the effects of asprosin on diabetes with a focus on serum glucose, irisin, ghrelin, leptin levels and hepatic levels of triglycerides (TG), cholesterol, low-density lipoprotein (LDL).
Methods:
Asprosin (10 µg/kg) was administered intraperitoneally four times at 3-day intervals and then blood and hepatic parameters above mentioned were investigated in control and diabetic mice.
Results:
The administration of asprosin increased blood glucose level in healthy animals (p = .05) whereas it did not change blood glucose level in diabetic animals. In addition, while asprosin decreased irisin level and increased ghrelin level, it did not change leptin level in diabetic mice. Therewithal, asprosin decreased the increasing levels in hepatic TG, cholesterol, and LDL in diabetic mice.
Conclusions:
Our novel findings implicate that asprosin may be a target molecule in preventing the development and complications of diabetes.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Dipeptidyl Peptidase 4 Inhibitors
Insulin: The Receptor and Signaling Pathways
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

